EUVIMEDEUVIMED entdecken
Open Access

Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry

Sara A Walton iD, Justin J Kim iD, Francesco Paoloni, Jean W Liew iD, Danielle Haradon iD, Jessica Haradon, Kathryn W Miller, Paul K Paik iD, Jamie E Chaft iD, Mark G Kris, Robert Hsu iD, Sarina A Piha-Paul iD und 9 weitere

JCO Precision Oncology · 2025-12 · (9)

DOI: 10.1200/po-25-00526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025-12. Verfasst von Sara A Walton und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA. Hauptthemen laut MEDLINE: Delayed Diagnosis, Carcinoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Diagnostic delays are common for patients with NUT carcinoma (NC), a cancer driven by NUT fusion oncoprotein. Rapid diagnosis is crucial for the best outcomes. We investigated NC's presenting features and associations with diagnostic delays. METHODS We manually reviewed medical records from US participants in the NC Registry (2007-2024). Baseline features were analyzed descriptively, and multivariable logistic regression was used to examine odds ratios for delays. RESULTS We analyzed 132 patients (median age 37 years). At presentation, 55% had metastatic disease and 64% had a thoracic primary. The median interval from symptom onset to diagnosis was 10 weeks (range, 1-165 weeks). The initial histopathologic diagnosis was poorly differentiated/squamous cell cancer in 52%, insufficient malignant cells in 14%, carcinoma in 12%, and NC in 22%. Immunohistochemistry (IHC) testing revealed NUT in 100%; 93% were keratin+, 88% p63+, 89% p40+, and 72% had Ki-67 ≥50%. IHC was used to diagnose NC in 79%. Nonthoracic primaries were associated with a longer time between symptom onset and NC diagnosis (odds ratio, 3.25). Of 32 patients who started treatment before diagnosis, 78% were on agents appropriate for NC. After a diagnosis of NC, 33% participated in clinical trials. CONCLUSION NC almost always presents as squamous/poorly differentiated non–small cell lung or head and neck cancer. Overall, 78% of patients were initially diagnosed as non-NC. Efforts to raise awareness, recognition, and rapid diagnosis of NC by both oncologists and pathologists are critical if we are to improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Delayed DiagnosisCarcinomaHumansFemaleMaleRegistriesAdultMiddle AgedAgedYoung AdultNeoplasm ProteinsNuclear Proteins

Substanzen

NUTM1 protein, humanNeoplasm ProteinsNuclear Proteins

Autor:innen und Institutionen

  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Boston University Chobanian and Avedisian School of Medicine, Boston, MA.
  • Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY.
  • Division of Medical Oncology, Department of Internal Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA.
  • Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

ORCID-Profile: Sara A Walton, Justin J Kim, Jean W Liew, Danielle Haradon, Paul K Paik, Jamie E Chaft, Robert Hsu, Sarina A Piha-Paul, Pasi A Jänne, Lynette M Sholl, Steven G DuBois, Glenn J Hanna, Geoffrey I Shapiro, Christopher A French, Jia Luo

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Walton, S. A., Kim, J. J., Paoloni, F., Liew, J. W., Haradon, D., Haradon, J., Miller, K. W., Paik, P. K., Chaft, J. E., Kris, M. G., Hsu, R., Piha-Paul, S. A., Rotow, J. K., Jänne, P. A., Barbie, D. A., Sholl, L. M., DuBois, S. G., Hanna, G. J., Shapiro, G. I., …, & Luo, J. (2025). Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry. JCO Precision Oncology. https://doi.org/10.1200/po-25-00526

Vancouver

Walton SA, Kim JJ, Paoloni F, Liew JW, Haradon D, Haradon J, et al. Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry. JCO Precision Oncology. 2025. doi:10.1200/po-25-00526

BibTeX
@article{Walton2025,
  author = {Walton, Sara A and Kim, Justin J and Paoloni, Francesco and Liew, Jean W and Haradon, Danielle and Haradon, Jessica and Miller, Kathryn W and Paik, Paul K and Chaft, Jamie E and Kris, Mark G and Hsu, Robert and Piha-Paul, Sarina A and Rotow, Julia K and Jänne, Pasi A and Barbie, David A and Sholl, Lynette M and DuBois, Steven G and Hanna, Glenn J and Shapiro, Geoffrey I and French, Christopher A and Luo, Jia},
  title = {Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00526}
}
Kostenlos starten →